Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Schell

Showing results (541-550 of 634) with videos related to

Pageof 64
Sort By:
Scientific Reports|October 26, 2012
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Jane L Messina, David A Fenstermacher, Steven Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerMark A Socinski, Michael J Schell, Amy Peterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Nature Communications|October 3, 2025
Persistence and clearance of oral human papillomavirus among a multi-national cohort of menBrittney L Dickey, Racheal S Dube Mandishora, Bradley Sirak, et al.
Cancer|September 26, 2001
Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trialM A Socinski, J G Rosenman, J Halle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
Oral Oncology|June 24, 2014
Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancerNikhil G Rao, Andy Trotti, Jongphil Kim, et al.
Blood|January 1, 1990
Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemiaC H Pui, F G Behm, B Singh, et al.
Pageof 64

Showing results (541-550 of 634) with videos related to

Sort By:
Pageof 64
Scientific Reports|October 26, 2012
12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?Jane L Messina, David A Fenstermacher, Steven Eschrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerMark A Socinski, Michael J Schell, Amy Peterman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Nature Communications|October 3, 2025
Persistence and clearance of oral human papillomavirus among a multi-national cohort of menBrittney L Dickey, Racheal S Dube Mandishora, Bradley Sirak, et al.
Cancer|September 26, 2001
Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trialM A Socinski, J G Rosenman, J Halle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
Oral Oncology|June 24, 2014
Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancerNikhil G Rao, Andy Trotti, Jongphil Kim, et al.
Blood|January 1, 1990
Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemiaC H Pui, F G Behm, B Singh, et al.
Pageof 64